Gillette Fusion and the Fine Art of the Con
Brand: Gillette
Execution: PR (news release)
Link: Click Here
Target: Wall Street
Rating: *
Reviewer: David
Description:
Gillette on Wednesday, September 14th announced the introduction of the world's first five-bladed razor, the Fusion. The Gillette Fusion razor (photo not available - the picture depicts the M3 Power, the most recent line extension to the Mach 3 franchise) which leapfrogs Schick's four-bladed quattro will sell for a 30% premium over current Mach 3 razors. This is in line with decades of successful new razor introductions for Gillette with steeply increased prices over previous generations.
What Works:
As a PR strategy, Gillette has certainly succeeded. The press has bought the PR story hook, line and sinker and even the Wall Street Journal, asking the soon to be $165mm richer Gillette CEO Jim Kilts seems content to end their in-depth analysis of the new product introduction with Kilts quote "Men are always looking for a better way to shave."
Businessweek virtually trips over itself to heap praise on Gillette after it cautions "...seems like a classic case of overkill," but quickly moves to explain that, "The overkill logic may seem compelling at first glance, but it's off-base on closer inspection. Despite its high price, the launch of Fusion is probably the closest thing to a slam-dunk in the intensely competitive consumer-products industry, where many new products never gain traction. It should be a huge boon to Procter & Gamble (PG ), which is expected to wrap up its acquisition of Gillette this fall." Of course, this is the same magazine that praised Enron, WorldCom and the AOL/Time Warner merger.
So clever is the spin on this announcement that Kilts and Gillette have successfully changed the dialogue on shaving from the question of reality (do five blades give you a better shave?) to perception (how do men feel about it). And the answer of course is that men are twice as likely to say they like the new shave.
Not a single of the myriad articles spawned by this announcement questions Gillette's test methodology. There are valid questions to ask. There is a reason that clinical trials are conducted using a double-blind method (where neither the patient nor the doctor or clinical investigator knows whether what's being administered is the test drug or a placebo). The reason is that when people are using something they know is new in a test they are more likely to think that it is helping them. So it is no surprise that men encountering 5 blades for the first time might think they are getting a better shave regardless of whether they actualy cut themselves less or are able to shave closer to the skin without abrasion or ingrown hairs. And there is similarly no evidence that Gillette has told anyone whether that is actually the case.
So Gillette has done a fantastic job in selling this new razor to the press, to Procter & Gamble (for whom the value of this razor is a key part of the acquisition price), and will undoubtedly do the same job on consumers when the blade hits shelves.